Final Trade: JNJ, NVO, UBER, BMY

Group 1 - The discussion highlights the performance of Johnson & Johnson (J&J) across its consumer products, MedTech, and oncology segments, indicating a diversified portfolio [1] - The overall sentiment towards the big pharmaceutical sector is positive, suggesting it is a favorable area for investment due to lower price-to-earnings (PE) ratios [1] - There is a mention of concerns regarding Uber's performance, indicating that it may be experiencing a challenging day, but some believe the market reaction could be overdone [1]